Modalities of treatment and 30-day outcomes of unselected patients older than 75 years with acute ST-elevation myocardial infarction

Data from the BLITZ study

Leonardo De Luca, Leonardo Bolognese, Gianni Casella, Stefano Savonitto, Lucio Gonzini, Antonio Di Chiara, Stefano De Servi, Salvatore Notaristefano, Laura Valagussa, Aldo P. Maggioni, Francesco Chiarella

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: The optimal treatment strategy for elderly patients presenting with ST-elevation myocardial infarction is still controversial and few investigations have studied this high-risk population in a community setting. Methods: We analyzed data from the BLITZ survey on patients with any acute myocardial infarction admitted to the Italian Coronary Care Unit (CCU) network, in order to assess current treatment strategies among unselected patients older than 75 years presenting with ST-elevation myocardial infarction. We also evaluated the 30-day rates of major adverse cardiovascular events (death/re-myocardial infarction/stroke) relative to different treatment strategies. Results: The registry included 1959 patients, of whom 529 (27%) were over 75 years old. According to the ECG on admission, 296 of these patients (56%) were classified as having ST-elevation myocardial infarction: 26 (8.8%) underwent primary percutaneous coronary intervention, 101 (34.1%) were treated with systemic thrombolysis, and the remaining 169 (57.1%) did not receive any early reperfusion therapy. At 30-day follow-up, the cumulative rate of major adverse cardiovascular events was not significantly different among the three treatment modality groups (31.4, 27.7, and 23.1% among no reperfusion, thrombolysis and primary percutaneous coronary intervention groups, respectively; P = 0.59). On multivariable analysis, age [odds ratio (OR) × 5-year increment 1.5; 95% confidence interval (CI) 1.2-2.0; P = 0.007], Killip class II-IV at admission (OR 3.7; 95% CI 2.1-6.3; P <0.0001), and coronary multivessel disease (OR 2.4; 95% CI 1.1-5.3; P = 0.03) were the only independent predictors of major adverse cardiovascular events. Conclusion: In a nationwide clinical practice, the vast majority of patients older than 75 years presenting with ST-elevation myocardial infarction does not receive any early reperfusion treatment and presents a significant incidence of major clinical events at 30 days.

Original languageEnglish
Pages (from-to)1045-1051
Number of pages7
JournalJournal of Cardiovascular Medicine
Volume9
Issue number10
DOIs
Publication statusPublished - Oct 2008

Fingerprint

Reperfusion
Odds Ratio
Confidence Intervals
Percutaneous Coronary Intervention
Myocardial Infarction
Therapeutics
Coronary Care Units
Patient Admission
Secondary Prevention
Coronary Disease
Registries
Electrocardiography
Stroke
ST Elevation Myocardial Infarction
Incidence
Population
Surveys and Questionnaires

Keywords

  • Elderly
  • Management
  • Primary angioplasty
  • Prognosis
  • Stelevation myocardial infarction
  • Thrombolysis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Modalities of treatment and 30-day outcomes of unselected patients older than 75 years with acute ST-elevation myocardial infarction : Data from the BLITZ study. / De Luca, Leonardo; Bolognese, Leonardo; Casella, Gianni; Savonitto, Stefano; Gonzini, Lucio; Di Chiara, Antonio; De Servi, Stefano; Notaristefano, Salvatore; Valagussa, Laura; Maggioni, Aldo P.; Chiarella, Francesco.

In: Journal of Cardiovascular Medicine, Vol. 9, No. 10, 10.2008, p. 1045-1051.

Research output: Contribution to journalArticle

De Luca, L, Bolognese, L, Casella, G, Savonitto, S, Gonzini, L, Di Chiara, A, De Servi, S, Notaristefano, S, Valagussa, L, Maggioni, AP & Chiarella, F 2008, 'Modalities of treatment and 30-day outcomes of unselected patients older than 75 years with acute ST-elevation myocardial infarction: Data from the BLITZ study', Journal of Cardiovascular Medicine, vol. 9, no. 10, pp. 1045-1051. https://doi.org/10.2459/JCM.0b013e32830eb6eb
De Luca, Leonardo ; Bolognese, Leonardo ; Casella, Gianni ; Savonitto, Stefano ; Gonzini, Lucio ; Di Chiara, Antonio ; De Servi, Stefano ; Notaristefano, Salvatore ; Valagussa, Laura ; Maggioni, Aldo P. ; Chiarella, Francesco. / Modalities of treatment and 30-day outcomes of unselected patients older than 75 years with acute ST-elevation myocardial infarction : Data from the BLITZ study. In: Journal of Cardiovascular Medicine. 2008 ; Vol. 9, No. 10. pp. 1045-1051.
@article{c94b0b3613874ce79a60e42678d8bfc6,
title = "Modalities of treatment and 30-day outcomes of unselected patients older than 75 years with acute ST-elevation myocardial infarction: Data from the BLITZ study",
abstract = "Background: The optimal treatment strategy for elderly patients presenting with ST-elevation myocardial infarction is still controversial and few investigations have studied this high-risk population in a community setting. Methods: We analyzed data from the BLITZ survey on patients with any acute myocardial infarction admitted to the Italian Coronary Care Unit (CCU) network, in order to assess current treatment strategies among unselected patients older than 75 years presenting with ST-elevation myocardial infarction. We also evaluated the 30-day rates of major adverse cardiovascular events (death/re-myocardial infarction/stroke) relative to different treatment strategies. Results: The registry included 1959 patients, of whom 529 (27{\%}) were over 75 years old. According to the ECG on admission, 296 of these patients (56{\%}) were classified as having ST-elevation myocardial infarction: 26 (8.8{\%}) underwent primary percutaneous coronary intervention, 101 (34.1{\%}) were treated with systemic thrombolysis, and the remaining 169 (57.1{\%}) did not receive any early reperfusion therapy. At 30-day follow-up, the cumulative rate of major adverse cardiovascular events was not significantly different among the three treatment modality groups (31.4, 27.7, and 23.1{\%} among no reperfusion, thrombolysis and primary percutaneous coronary intervention groups, respectively; P = 0.59). On multivariable analysis, age [odds ratio (OR) × 5-year increment 1.5; 95{\%} confidence interval (CI) 1.2-2.0; P = 0.007], Killip class II-IV at admission (OR 3.7; 95{\%} CI 2.1-6.3; P <0.0001), and coronary multivessel disease (OR 2.4; 95{\%} CI 1.1-5.3; P = 0.03) were the only independent predictors of major adverse cardiovascular events. Conclusion: In a nationwide clinical practice, the vast majority of patients older than 75 years presenting with ST-elevation myocardial infarction does not receive any early reperfusion treatment and presents a significant incidence of major clinical events at 30 days.",
keywords = "Elderly, Management, Primary angioplasty, Prognosis, Stelevation myocardial infarction, Thrombolysis",
author = "{De Luca}, Leonardo and Leonardo Bolognese and Gianni Casella and Stefano Savonitto and Lucio Gonzini and {Di Chiara}, Antonio and {De Servi}, Stefano and Salvatore Notaristefano and Laura Valagussa and Maggioni, {Aldo P.} and Francesco Chiarella",
year = "2008",
month = "10",
doi = "10.2459/JCM.0b013e32830eb6eb",
language = "English",
volume = "9",
pages = "1045--1051",
journal = "Journal of Cardiovascular Medicine",
issn = "1558-2027",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Modalities of treatment and 30-day outcomes of unselected patients older than 75 years with acute ST-elevation myocardial infarction

T2 - Data from the BLITZ study

AU - De Luca, Leonardo

AU - Bolognese, Leonardo

AU - Casella, Gianni

AU - Savonitto, Stefano

AU - Gonzini, Lucio

AU - Di Chiara, Antonio

AU - De Servi, Stefano

AU - Notaristefano, Salvatore

AU - Valagussa, Laura

AU - Maggioni, Aldo P.

AU - Chiarella, Francesco

PY - 2008/10

Y1 - 2008/10

N2 - Background: The optimal treatment strategy for elderly patients presenting with ST-elevation myocardial infarction is still controversial and few investigations have studied this high-risk population in a community setting. Methods: We analyzed data from the BLITZ survey on patients with any acute myocardial infarction admitted to the Italian Coronary Care Unit (CCU) network, in order to assess current treatment strategies among unselected patients older than 75 years presenting with ST-elevation myocardial infarction. We also evaluated the 30-day rates of major adverse cardiovascular events (death/re-myocardial infarction/stroke) relative to different treatment strategies. Results: The registry included 1959 patients, of whom 529 (27%) were over 75 years old. According to the ECG on admission, 296 of these patients (56%) were classified as having ST-elevation myocardial infarction: 26 (8.8%) underwent primary percutaneous coronary intervention, 101 (34.1%) were treated with systemic thrombolysis, and the remaining 169 (57.1%) did not receive any early reperfusion therapy. At 30-day follow-up, the cumulative rate of major adverse cardiovascular events was not significantly different among the three treatment modality groups (31.4, 27.7, and 23.1% among no reperfusion, thrombolysis and primary percutaneous coronary intervention groups, respectively; P = 0.59). On multivariable analysis, age [odds ratio (OR) × 5-year increment 1.5; 95% confidence interval (CI) 1.2-2.0; P = 0.007], Killip class II-IV at admission (OR 3.7; 95% CI 2.1-6.3; P <0.0001), and coronary multivessel disease (OR 2.4; 95% CI 1.1-5.3; P = 0.03) were the only independent predictors of major adverse cardiovascular events. Conclusion: In a nationwide clinical practice, the vast majority of patients older than 75 years presenting with ST-elevation myocardial infarction does not receive any early reperfusion treatment and presents a significant incidence of major clinical events at 30 days.

AB - Background: The optimal treatment strategy for elderly patients presenting with ST-elevation myocardial infarction is still controversial and few investigations have studied this high-risk population in a community setting. Methods: We analyzed data from the BLITZ survey on patients with any acute myocardial infarction admitted to the Italian Coronary Care Unit (CCU) network, in order to assess current treatment strategies among unselected patients older than 75 years presenting with ST-elevation myocardial infarction. We also evaluated the 30-day rates of major adverse cardiovascular events (death/re-myocardial infarction/stroke) relative to different treatment strategies. Results: The registry included 1959 patients, of whom 529 (27%) were over 75 years old. According to the ECG on admission, 296 of these patients (56%) were classified as having ST-elevation myocardial infarction: 26 (8.8%) underwent primary percutaneous coronary intervention, 101 (34.1%) were treated with systemic thrombolysis, and the remaining 169 (57.1%) did not receive any early reperfusion therapy. At 30-day follow-up, the cumulative rate of major adverse cardiovascular events was not significantly different among the three treatment modality groups (31.4, 27.7, and 23.1% among no reperfusion, thrombolysis and primary percutaneous coronary intervention groups, respectively; P = 0.59). On multivariable analysis, age [odds ratio (OR) × 5-year increment 1.5; 95% confidence interval (CI) 1.2-2.0; P = 0.007], Killip class II-IV at admission (OR 3.7; 95% CI 2.1-6.3; P <0.0001), and coronary multivessel disease (OR 2.4; 95% CI 1.1-5.3; P = 0.03) were the only independent predictors of major adverse cardiovascular events. Conclusion: In a nationwide clinical practice, the vast majority of patients older than 75 years presenting with ST-elevation myocardial infarction does not receive any early reperfusion treatment and presents a significant incidence of major clinical events at 30 days.

KW - Elderly

KW - Management

KW - Primary angioplasty

KW - Prognosis

KW - Stelevation myocardial infarction

KW - Thrombolysis

UR - http://www.scopus.com/inward/record.url?scp=55249120049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55249120049&partnerID=8YFLogxK

U2 - 10.2459/JCM.0b013e32830eb6eb

DO - 10.2459/JCM.0b013e32830eb6eb

M3 - Article

VL - 9

SP - 1045

EP - 1051

JO - Journal of Cardiovascular Medicine

JF - Journal of Cardiovascular Medicine

SN - 1558-2027

IS - 10

ER -